

Tom W J Huizinga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/973247/publications.pdf>

Version: 2024-02-01

581
papers

55,741
citations

2696

98
h-index

1719

219
g-index

598
all docs

598
docs citations

598
times ranked

45375
citing authors

#	ARTICLE	IF	CITATIONS
1	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	0.6	2
2	Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e69-e69.	0.5	13
3	Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 141-143.	0.5	11
4	Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 169-174.	0.5	14
5	To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2022, 9, e000629.	1.1	0
6	Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry. <i>Rheumatology International</i> , 2022, , .	1.5	1
7	Management of contemporary early undifferentiated arthritis: data on EULAR's recommendation on the risk of persistent disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 740-741.	0.5	3
8	IgG Anti-“Citruillinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross-sectional Study Encompassing ~1,500 Samples. <i>Arthritis and Rheumatology</i> , 2022, 74, 1147-1158.	2.9	23
9	MRI-Based Classification of Neuropsychiatric Systemic Lupus Erythematosus Patients With Self-Supervised Contrastive Learning. <i>Frontiers in Neuroscience</i> , 2022, 16, 695888.	1.4	3
10	No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1197-1199.	0.5	1
11	Gastrointestinal symptom severity and progression in systemic sclerosis. <i>Rheumatology</i> , 2022, , .	0.9	2
12	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	0.9	2
13	In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. <i>Rheumatology</i> , 2022, 62, 407-416.	0.9	6
14	Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. <i>Science Advances</i> , 2022, 8, eabm1759.	4.7	30
15	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.5	14
16	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. <i>RMD Open</i> , 2022, 8, e002079.	1.8	9
17	Rheumatic?â€”A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Pilot Validation Study. <i>Frontiers in Medicine</i> , 2022, 9, 774945.	1.2	5
18	ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation. <i>Rheumatology</i> , 2022, 62, 124-134.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 402-409.	1.0	6
20	Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2021, 73, 722-731.	1.5	4
21	Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. <i>Rheumatology and Therapy</i> , 2021, 8, 41-61.	1.1	35
22	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 921-930.	2.9	17
23	Quantitative susceptibility mapping in the thalamus and basal ganglia of systemic lupus erythematosus patients with neuropsychiatric complaints. <i>NeuroImage: Clinical</i> , 2021, 30, 102637.	1.4	2
24	Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. <i>Rheumatology</i> , 2021, 60, 3646-3655.	0.9	22
25	Earlier chronotype in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 2185-2192.	1.0	9
26	Phenotype and treatment of elderly onset compared with younger onset rheumatoid arthritis patients in international daily practice. <i>Rheumatology</i> , 2021, 60, 4801-4810.	0.9	7
27	Onset of rheumatoid arthritis after COVID-19: coincidence or connected?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1096-1098.	0.5	53
28	Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. <i>Lupus</i> , 2021, 30, 1124-1132.	0.8	17
29	Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis. <i>PLoS ONE</i> , 2021, 16, e0247847.	1.1	2
30	Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI. <i>European Radiology</i> , 2021, 31, 8208-8217.	2.3	13
31	Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1364-1365.	0.5	0
32	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2338-2347.	2.9	14
33	Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2021, 8, e000472.	1.1	6
34	Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1124-1129.	0.5	8
35	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. <i>RMD Open</i> , 2021, 7, e001524.	1.8	3
36	White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms. <i>RMD Open</i> , 2021, 7, e001650.	1.8	4

#	ARTICLE	IF	CITATIONS
37	A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with LÃ¶fgrenâ€™s Syndrome and Alters Receptor Expression as well as Functional Response. <i>Cells</i> , 2021, 10, 1967.	1.8	3
38	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. <i>Arthritis Research and Therapy</i> , 2021, 23, 230.	1.6	12
39	Dissociation in SLE: A part of lupus fog?. <i>Lupus</i> , 2021, 30, 096120332110503.	0.8	1
40	Neuropsychiatric systemic lupus erythematosus is associated with a distinct type and shape of cerebral white matter hyperintensities. <i>Rheumatology</i> , 2021, , .	0.9	0
41	Longitudinal changes in cerebral white matter microstructure in newly diagnosed systemic lupus erythematosus patients. <i>Rheumatology</i> , 2021, 60, 2678-2687.	0.9	3
42	Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e124-e124.	0.5	14
43	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 140-148.	1.6	13
44	An overview of autoantibodies in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 110, 102392.	3.0	163
45	Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol. <i>Trials</i> , 2020, 21, 15.	0.7	3
46	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. <i>Journal of Immunology</i> , 2020, 205, 2840-2849.	0.4	33
47	Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	53
48	Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. <i>Lupus</i> , 2020, 29, 1892-1901.	0.8	19
49	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020, 6, e001370.	1.8	23
50	P39â€™...Longitudinal changes of cerebral white matter tissue microstructure in early-onset systemic lupus erythematosus. , 2020, , .		0
51	Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. <i>PLoS Medicine</i> , 2020, 17, e1003296.	3.9	52
52	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. <i>Arthritis Care and Research</i> , 2020, , .	1.5	13
53	Interpreting big-data analysis of retrospective observational data. <i>Lancet Rheumatology</i> , The, 2020, 2, e652-e653.	2.2	6
54	Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?. <i>RMD Open</i> , 2020, 6, e001242.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.5	32
56	Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	31
57	Body mass index and treatment survival in patients with RA starting treatment with TNF \pm -inhibitors: long-term follow-up in the real-life METEOR registry. <i>RMD Open</i> , 2020, 6, e001203.	1.8	3
58	Association of Anti α -Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti α -Topoisomerase I α -Positive Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1897-1904.	2.9	18
59	Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 472-480.	0.5	74
60	Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study. <i>Musculoskeletal Care</i> , 2020, 18, 177-186.	0.6	5
61	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2020, 39, 1543-1549.	1.0	4
62	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
63	On using machine learning algorithms to define clinically meaningful patient subgroups. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e154-e154.	0.5	4
64	Disruptive innovation in rheumatology: new networks of global public α -private partnerships are needed to take advantage of scientific progress. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 553-555.	0.5	1
65	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. <i>Arthritis Research and Therapy</i> , 2020, 22, 85.	1.6	4
66	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
67	Machine Learning Electronic Health Record Identification of Patients with Rheumatoid Arthritis: Algorithm Pipeline Development and Validation Study. <i>JMIR Medical Informatics</i> , 2020, 8, e23930.	1.3	29
68	Suspected Transverse Myelitis with Normal MRI and CSF Findings in a Patient with Lupus: What to Do? A Case Series and Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 3173-3186.	1.0	4
69	One year in review 2020: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 181-194.	0.4	10
70	Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 25-28.	0.4	2
71	Title is missing!. , 2020, 17, e1003296.		0
72	Title is missing!. , 2020, 17, e1003296.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003296.		0
74	Title is missing!. , 2020, 17, e1003296.		0
75	Title is missing!. , 2020, 17, e1003296.		0
76	Title is missing!. , 2020, 17, e1003296.		0
77	Treat-to-Target Strategies in Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 322, 83.	3.8	2
78	On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1616-1620.	0.5	35
79	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. Rheumatology, 2019, 58, 730-732.	0.9	9
80	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Research and Therapy, 2019, 21, 28.	1.6	33
81	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. Annals of the Rheumatic Diseases, 2019, 78, 908-916.	0.5	34
82	Performance of the proposed ACRâ€EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms. RMD Open, 2019, 5, e000895.	1.8	14
83	<i>N</i>â€Linked Glycans in the Variable Domain of IgG Antiâ€CitruLLinated Protein Antibodies Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1626-1633.	2.9	80
84	ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Research and Therapy, 2019, 21, 121.	1.6	20
85	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 2019, 5, e000840.	1.8	8
86	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for <i>CD40</i> and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.5	25
87	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. Journal of Rheumatology, 2019, 46, 405-415.	1.0	17
88	Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients. Scientific Reports, 2019, 9, 4521.	1.6	29
89	Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry. RMD Open, 2019, 5, e000969.	1.8	4
90	Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12â€months of tapering anti-rheumatic drugs. Arthritis Research and Therapy, 2019, 21, 268.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 149-153.	0.9	11
92	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2019, 7, 6-11.	1.6	118
93	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 967-975.	1.6	46
94	Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e1-e1.	0.5	25
95	Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 82-87.	0.4	2
96	B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212052.	0.5	51
97	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 360-363.	0.6	7
98	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. <i>RMD Open</i> , 2018, 4, e000564.	1.8	29
99	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 270-275.	0.6	2
100	The B cell response to citrullinated antigens in the development of rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 157-169.	3.5	88
101	Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. <i>Arthritis Research and Therapy</i> , 2018, 20, 33.	1.6	39
102	Is optimising gout treatment the key to closing the mortality gap in gout patients?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e2-e2.	0.5	1
103	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1087-1088.	0.5	14
104	Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 111-118.	0.5	51
105	Preventing progression from arthralgia to arthritis: targeting the right patients. <i>Nature Reviews Rheumatology</i> , 2018, 14, 32-41.	3.5	91
106	PS7:129 Synergetic b-cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory sle. , 2018, , .		1
107	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1757-1764.	0.5	113
108	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1707-1720.	0.9	25

#	ARTICLE	IF	CITATIONS
109	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 2225-2231.	1.5	4
110	Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. <i>Nature Genetics</i> , 2018, 50, 1366-1374.	9.4	122
111	Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1721-1731.	2.9	81
112	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. <i>Rheumatology</i> , 2018, 57, 1583-1591.	0.9	11
113	MR signal intensity: staying on the bright side in MR image interpretation. <i>RMD Open</i> , 2018, 4, e000728.	1.8	56
114	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1836-1838.	0.5	12
115	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. <i>Rheumatology</i> , 2018, 57, 1423-1431.	0.9	31
116	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
117	Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000649.	1.8	7
118	THU0024...Treatment with immune checkpoint inhibitors and the break of b-cell tolerance to autoantigens. , 2018, , .		1
119	OPO313...Molecular analysis of anti-citrullinated protein antibody variable regions indicates aberrant selection processes during acpa b-cell development. , 2018, , .		0
120	Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for Fc γ RI in the pathogenesis of synovial inflammation. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 284-293.	0.4	6
121	To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 109-117.	0.4	4
122	Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 278-287.	2.5	82
123	Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. <i>Arthritis and Rheumatology</i> , 2017, 69, 926-931.	2.9	41
124	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
125	Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 1150-1160.	0.6	52
126	Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus. <i>Rheumatology</i> , 2017, 56, 1407-1416.	0.9	20

#	ARTICLE	IF	CITATIONS
127	08.18â€¦Anti-citrullinated protein antibodies: a marker of cardiovascular disease and mortality in patients without rheumatoid arthritis. , 2017, , .		0
128	Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. Rheumatology, 2017, 56, 1367-1377.	0.9	29
129	Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. International Journal of Cardiology, 2017, 240, 20-24.	0.8	11
130	Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases, 2017, 76, 1449-1457.	0.5	27
131	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Research and Therapy, 2017, 19, 115.	1.6	23
132	FR10090â€¦Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis. , 2017, , .		4
133	Auto-antibodies and cancer in systemic sclerosis. Autoimmunity Reviews, 2017, 16, 883-884.	2.5	7
134	Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1751-1754.	0.5	53
135	Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 249-262.	1.2	88
136	Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort. Journal of Rheumatology, 2017, 44, 1659-1666.	1.0	44
137	Rituximab in early systemic sclerosis. RMD Open, 2017, 3, e000384.	1.8	47
138	Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2017, 43, 347-361.	0.8	13
139	Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1915-1923.	0.5	36
140	Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents. RMD Open, 2017, 3, e000568.	1.8	15
141	05.11â€¦Antisense long noncoding rnas are deregulated in skin tissue of ssc patients. , 2017, , .		0
142	Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study. RMD Open, 2017, 3, e000419.	1.8	20
143	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics, 2017, 18, 945-953.	0.6	6
144	Rheumatologistsâ€™ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission. Clinical Rheumatology, 2017, 36, 317-326.	1.0	10

#	ARTICLE	IF	CITATIONS
145	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. <i>Rheumatology</i> , 2017, 56, 1721-1728.	0.9	4
146	Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. <i>Rheumatology</i> , 2017, 56, 77-86.	0.9	90
147	Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 735-741.	2.9	8
148	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 717-723.	1.5	20
149	Using a reference when defining an abnormal MRI reduces false-positive MRI results—a longitudinal study in two cohorts at risk for rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1700-1706.	0.9	38
150	AB0084—Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients. , 2017, , .		0
151	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 190.	1.6	20
152	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 258.	1.6	3
153	P5410 Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
154	Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue. <i>World Journal of Gastroenterology</i> , 2017, 23, 1018.	1.4	12
155	The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. <i>Arthritis and Rheumatology</i> , 2016, 68, 1080-1088.	2.9	45
156	Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. <i>Rheumatology</i> , 2016, 55, kev342.	0.9	4
157	The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA: Table 1. <i>Rheumatology</i> , 2016, 55, 199-209.	0.9	112
158	The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 275-281.	2.0	18
159	Human mast cells costimulate T cells through a CD28-independent interaction. <i>European Journal of Immunology</i> , 2016, 46, 1132-1141.	1.6	9
160	Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis. <i>RMD Open</i> , 2016, 2, e000159.	1.8	40
161	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 285.	1.6	43
162	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51

#	ARTICLE	IF	CITATIONS
163	Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2201-2207.	0.5	23
164	A2.10â€¦The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A19.1-A19.	0.5	0
165	TAC-TIC use of tacrolimus-based regimens in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016, 3, e000169.	1.1	24
166	Aesthetic dissatisfaction in patients with hand osteoarthritis and its impact on daily life. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 219-223.	0.6	9
167	Predictive factors of radiological progression after 2â€¦years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , 2016, 2, e000172.	1.8	13
168	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	1.8	38
169	Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons. <i>Arthritis Research and Therapy</i> , 2016, 18, 245.	1.6	19
170	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1501-1505.	0.5	17
171	Efficacy of tofacitinib monotherapy in methotrexate-naïve patients with early or established rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000262.	1.8	24
172	Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. <i>Annals of Internal Medicine</i> , 2016, 164, 523.	2.0	95
173	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
174	The increased ability to present citrullinated peptides is not unique to HLA-SE molecules: arginine-to-citrulline conversion also enhances peptide affinity for HLA-DQ molecules. <i>Arthritis Research and Therapy</i> , 2016, 18, 254.	1.6	23
175	Drivers of costly treatment strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2016, 388, 213-214.	6.3	5
176	A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. <i>Nature Genetics</i> , 2016, 48, 803-810.	9.4	62
177	Repeated FcÎµRI triggering reveals modified mast cell function related to chronic allergic responses in tissue. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 869-880.	1.5	19
178	Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1386-1393.	0.9	22
179	The production and secretion of complement component C1q by human mast cells. <i>Molecular Immunology</i> , 2016, 78, 164-170.	1.0	34
180	Older age is associated with more MRI-detected inflammation in hand and foot joints. <i>Rheumatology</i> , 2016, 55, 2212-2219.	0.9	16

#	ARTICLE	IF	CITATIONS
181	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 198.	1.6	56
182	Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. <i>Arthritis Research and Therapy</i> , 2016, 18, 138.	1.6	31
183	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
184	A2.15â€¦Ra phenotype at presentation differs among patients with few versus many autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A21.1-A21.	0.5	0
185	FRI0086â€¦Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 458.1-458.	0.5	0
186	Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial. <i>RMD Open</i> , 2016, 2, e000143.	1.8	12
187	Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). <i>Arthritis Research and Therapy</i> , 2016, 18, 23.	1.6	37
188	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 33.	0.8	2
189	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 578-585.	0.5	161
190	Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 357-366.	0.9	32
191	Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. <i>Brain</i> , 2016, 139, 1447-1457.	3.7	54
192	Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1891-1898.	0.5	12
193	Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1824-1830.	0.5	126
194	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1308-1314.	0.5	84
195	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1170-1176.	0.5	72
196	Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S87-S90.	0.4	7
197	THU0114â€¦Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234.3-235.	0.5	4
198	FRI0186â€¦Impact of Concomitant Methotrexate Dose on the Efficacy and Safety of Sarilumab for Treatment of Moderate-to-Severe Rheumatoid Arthritis: The Mobility Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 491.2-492.	0.5	0

#	ARTICLE	IF	CITATIONS
199	A prediction model for progressive disease in systemic sclerosis. <i>RMD Open</i> , 2015, 1, e000113.	1.8	5
200	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. <i>Arthritis Research and Therapy</i> , 2015, 17, 232.	1.6	88
201	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 222.	1.6	21
202	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 339.	1.6	67
203	Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. <i>Arthritis Research and Therapy</i> , 2015, 17, 108.	1.6	14
204	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 209.	1.6	63
205	Response to "Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis" authors' reply. <i>Arthritis Research and Therapy</i> , 2015, 17, 171.	1.6	0
206	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. <i>Arthritis Research and Therapy</i> , 2015, 17, 276.	1.6	21
207	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. <i>Arthritis Research and Therapy</i> , 2015, 17, 325.	1.6	16
208	A1.25...Visualisation and characterisation of citrullinated antigen-specific B cells from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A11.1-A11.	0.5	2
209	FR10152...On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 477.2-478.	0.5	1
210	AB0446...Treatment Effects and Minimal Clinically Important Differences in Patient-Reported Outcomes Following Treatment and Withdrawal of Abatacept, Methotrexate Or Combination Therapy in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1044.1-1044.	0.5	1
211	Ability of Interleukin-33 and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses. <i>Arthritis and Rheumatology</i> , 2015, 67, 2343-2353.	2.9	50
212	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 409-423.	0.5	86
213	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1424-1437.	2.9	213
214	Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 883-889.	0.5	18
215	Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1762-1766.	1.5	11
216	IL2RA is associated with persistence of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 244.	1.6	19

#	ARTICLE	IF	CITATIONS
217	Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1225-1232.	0.5	92
218	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. <i>Immunobiology</i> , 2015, 220, 422-427.	0.8	15
219	Continued Participation in a Ten-Year Tight Control Treat-to-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing their Best?. <i>Arthritis Care and Research</i> , 2015, 67, 739-745.	1.5	10
220	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 19-26.	0.5	201
221	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. <i>Journal of Rheumatology</i> , 2015, 42, 572-579.	1.0	107
222	Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?. <i>Journal of Internal Medicine</i> , 2015, 277, 178-187.	2.7	16
223	A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 1.	1.6	135
224	Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment. <i>Rheumatology</i> , 2015, 54, 1380-1384.	0.9	11
225	Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?. <i>European Radiology</i> , 2015, 25, 1520-1527.	2.3	42
226	Mortality in osteoarthritis patients. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 70-73.	0.6	27
227	Immunogenetics of rheumatoid arthritis: Understanding functional implications. <i>Journal of Autoimmunity</i> , 2015, 64, 74-81.	3.0	65
228	Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study. <i>Journal of Rheumatology</i> , 2015, 42, 1383-1391.	1.0	23
229	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1930-1932.	0.9	25
230	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. <i>Journal of Autoimmunity</i> , 2015, 62, 39-44.	3.0	33
231	2014 treat-to-target RA recommendations" strategy is key. <i>Nature Reviews Rheumatology</i> , 2015, 11, 509-511.	3.5	14
232	A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. <i>NeuroImage: Clinical</i> , 2015, 8, 337-344.	1.4	49
233	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 949-950.	0.5	16
234	IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. <i>Rheumatology</i> , 2015, 54, 728-735.	0.9	48

#	ARTICLE	IF	CITATIONS
235	A7.4â€¦The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A76.1-A76.	0.5	0
236	Evaluation of Magnetic Resonance Imagingâ€œDetected Tenosynovitis in the Hand and Wrist in Early Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 869-876.	2.9	58
237	Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. <i>RMD Open</i> , 2015, 1, e000041-e000041.	1.8	57
238	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. <i>Nature Genetics</i> , 2015, 47, 1085-1090.	9.4	164
239	THU0040â€¦In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 206.4-207.	0.5	0
240	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015, 44, 1706-1721.	0.9	53
241	Abatacept decreases disease activity in the absence of CD4+ T cells in a collagen-induced arthritis model. <i>Arthritis Research and Therapy</i> , 2015, 17, 220.	1.6	18
242	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	0.9	23
243	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234-241.	0.5	225
244	Seronegative and seropositive RA: alike but different?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 8-9.	3.5	49
245	Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 876-882.	0.5	11
246	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e87645.	1.1	34
247	FRI0402â€¦Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 532.3-533.	0.5	0
248	87.â€œComparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis. <i>Rheumatology</i> , 2014, 53, i88-i89.	0.9	1
249	Differential methylation within the major histocompatibility complex region in rheumatoid arthritis: a replication study. <i>Rheumatology</i> , 2014, 53, 2317-2318.	0.9	14
250	A1.49â€¦Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A21.1-A21.	0.5	0
251	Autoimmunity: Break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. <i>Immunology Letters</i> , 2014, 162, 150-162.	1.1	4
252	Are Baseline High Molecular Weight Adiponectin Levels Associated with Radiographic Progression in Rheumatoid Arthritis and Osteoarthritis?. <i>Journal of Rheumatology</i> , 2014, 41, 853-857.	1.0	12

#	ARTICLE	IF	CITATIONS
253	Belimumab after rituximab as maintenance therapy in lupus nephritis. <i>Rheumatology</i> , 2014, 53, 2122-2124.	0.9	60
254	Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 396-400.	0.5	45
255	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 430.	1.6	5
256	Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study. <i>Journal of Rheumatology</i> , 2014, 41, 1630-1637.	1.0	23
257	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. <i>Autoimmunity Reviews</i> , 2014, 13, 225-230.	2.5	99
258	The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2014, 36, 313-325.	2.8	25
259	Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). <i>Lupus</i> , 2014, 23, 31-38.	0.8	94
260	Genetics of rheumatoid arthritis contributes to biology and drug discovery. <i>Nature</i> , 2014, 506, 376-381.	13.7	1,974
261	A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study. <i>Journal of Rheumatology</i> , 2014, 41, 2114-2119.	1.0	38
262	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 270-276.	0.5	40
263	Sarilumab, a fully human monoclonal antibody against IL-6R α in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1626-1634.	0.5	173
264	HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 633-634.	0.5	0
265	Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 567-572.	0.5	25
266	Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?. <i>European Radiology</i> , 2014, 24, 2614-2622.	2.3	34
267	Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in L \ddot{a} ngren \ddot{a} s syndrome. <i>Cytokine</i> , 2014, 69, 272-276.	1.4	12
268	Is HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 1948-1951.	1.0	1
269	IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activation. <i>European Journal of Immunology</i> , 2014, 44, 3045-3055.	1.6	32
270	Health-care utilization in Dutch systemic sclerosis patients. <i>Clinical Rheumatology</i> , 2014, 33, 825-832.	1.0	12

#	ARTICLE	IF	CITATIONS
271	Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. <i>Clinical Rheumatology</i> , 2014, 33, 461-466.	1.0	15
272	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R108.	1.6	19
273	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. <i>American Journal of Human Genetics</i> , 2014, 94, 522-532.	2.6	156
274	Activation of human basophils by combined toll-like receptor and μ RI triggering can promote Th2 skewing of naive Th helper cells. <i>European Journal of Immunology</i> , 2014, 44, 386-396.	1.6	59
275	Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2038-2046.	0.5	40
276	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 780-783.	0.5	185
277	Follow-up study of inflammatory ultrasound features in hand osteoarthritis over a period of 3 months: variable as well as constant. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 40-43.	0.6	27
278	Degree of synovitis on MRI by comprehensive whole knee semi-quantitative scoring method correlates with histologic and macroscopic features of synovial tissue inflammation in knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 1606-1613.	0.6	51
279	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1761-1768.	0.5	111
280	HLA and rheumatoid arthritis: How do they connect?. <i>Annals of Medicine</i> , 2014, 46, 304-310.	1.5	26
281	A1.28...Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A11.3-A12.	0.5	1
282	A1.29...In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinaged protein antibodies, but with the presence of several autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A12.1-A12.	0.5	0
283	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. <i>PLoS ONE</i> , 2014, 9, e102163.	1.1	37
284	Biomarkers for Radiographic Progression in Rheumatoid Arthritis. <i>Current Pharmaceutical Design</i> , 2014, 21, 147-169.	0.9	33
285	An innovative care model coordinated by a physical therapist and nurse practitioner for osteoarthritis of the hip and knee in specialist care: a prospective study. <i>Rheumatology International</i> , 2013, 33, 1821-1828.	1.5	14
286	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1259-1263.	0.5	69
287	Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii76-ii79.	0.5	62
288	A7.10...Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A51.2-A51.	0.5	1

#	ARTICLE	IF	CITATIONS
289	Demyelinating disease in SLE: Is it multiple sclerosis or lupus?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 405-424.	1.4	45
290	An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis and Cartilage, 2013, 21, 918-922.	0.6	108
291	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1375-1381.	0.5	94
292	CD5 ⁺ CD4 ⁺ T cells modulate T _H 1 cell response via inhibition of IL-12 production by DCs. European Journal of Immunology, 2013, 43, 439-446.	1.6	4
293	In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Annals of the Rheumatic Diseases, 2013, 72, 930-934.	0.5	68
294	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1897-1904.	0.5	114
295	Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, 974-978.	0.5	35
296	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the α -AMC-Senshu TM method. Annals of the Rheumatic Diseases, 2013, 72, 148-150.	0.5	73
297	Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus, 2013, 22, 171-179.	0.8	28
298	Association study of candidate genes for the progression of hand osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, 565-569.	0.6	26
299	Autoimmunity in rheumatoid arthritis: different antigens – common principles. Annals of the Rheumatic Diseases, 2013, 72, ii132-ii136.	0.5	44
300	Personalized medicine: predicting responses to therapy in patients with RA. Current Opinion in Pharmacology, 2013, 13, 463-469.	1.7	30
301	MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1540-1544.	0.5	48
302	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SPondyloArthritis international Society (ASAS)-cohort. Annals of the Rheumatic Diseases, 2013, 72, 1646-1653.	0.5	127
303	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 769-775.	0.5	70
304	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Annals of the Rheumatic Diseases, 2013, 72, 1059-1063.	0.5	21
305	A7.1 – A Genetic Variant in the Region of MMP-9 is Associated with Serum Levels and Progression of Joint Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.1-A48.	0.5	2
306	Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 307-308.	0.5	10

#	ARTICLE	IF	CITATIONS
307	Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 624-629.	1.0	16
308	Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 182-189.	0.6	27
309	Pathogenic relevance of anti-citrullinated vimentin antibodies: Comment on the article by Montes et al. <i>Arthritis and Rheumatism</i> , 2013, 65, 541-542.	6.7	0
310	Brief Report: Anti-Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 911-915.	6.7	164
311	Editorial: Family Studies in the Information Age. <i>Arthritis and Rheumatism</i> , 2013, 65, 2762-2764.	6.7	0
312	Metabolic Profiling Reveals Differences in Concentrations of Oxylipins and Fatty Acids Secreted by the Infrapatellar Fat Pad of Donors With End-stage Osteoarthritis and Normal Donors. <i>Arthritis and Rheumatism</i> , 2013, 65, 2606-2614.	6.7	41
313	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
314	Allele dose association of the C5orf30rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, n/a-n/a.	6.7	20
315	Evaluating joint destruction in rheumatoid arthritis: is it necessary to radiograph both hands and feet?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 345-349.	0.5	23
316	A5.4...Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.2-A31.	0.5	2
317	Serum Pyridinoline Levels and Prediction of Severity of Joint Destruction in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1303-1306.	1.0	17
318	Dr. Zirkzee, et al reply. <i>Journal of Rheumatology</i> , 2013, 40, 204.2-204.	1.0	0
319	Communication between human mast cells and CD4 ⁺ T cells through antigen-dependent interactions. <i>European Journal of Immunology</i> , 2013, 43, 1758-1768.	1.6	49
320	Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 43-50.	0.5	259
321	Platelets and autoimmunity. <i>European Journal of Clinical Investigation</i> , 2013, 43, 746-757.	1.7	98
322	Adipocyte-derived lipids modulate CD4 ⁺ T cell function. <i>European Journal of Immunology</i> , 2013, 43, 1578-1587.	1.6	71
323	Adipocytes Modulate the Phenotype of Human Macrophages through Secreted Lipids. <i>Journal of Immunology</i> , 2013, 191, 1356-1363.	0.4	41
324	Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1295-1301.	0.5	32

#	ARTICLE	IF	CITATIONS
325	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	9.4	24
326	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1302-1307.	0.5	17
327	A1.1â€¦Anti-Citrullinated Protein Antibody Specific Fc Glycosylation Patterns in Arthralgia Patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A1.1-A1.	0.5	1
328	A1.8â€¦Magnetic Resonance Imaging of Hand and Foot Joints of Patients with ACPA Positive Arthralgia without Clinical Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A3.3-A3.	0.5	1
329	A4.2â€¦Adipocytes Modulate T Cell Function through Release of Lipids. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A24.1-A24.	0.5	0
330	OP0193â€¦Motivations for seeking medical advice in arthralgia and early arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 120.1-120.	0.5	0
331	A10.21â€¦Toll-Like Receptor Triggering of Human Basophils May Synergise with IgE-Mediated Activation in ACPA+ RA. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A79.2-A79.	0.5	0
332	OP0134â€¦Risk stratification in patients with undifferentiated arthritis according to the 2010 ACR/EULAR criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 98.3-99.	0.5	0
333	THU0020â€¦Serum pyridinoline levels predict the severity of future joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 160.2-160.	0.5	0
334	A5.29â€¦Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A41.1-A41.	0.5	0
335	A4.3â€¦Adipocytes Modulate the Phenotype of Macrophages through Secreted Lipids. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A24.2-A24.	0.5	0
336	A4.5â€¦Do High Molecular Weight Adiponectin Levels Associate with Radiographic Progression in early Rheumatoid Arthritis and Hand Osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A25.1-A25.	0.5	1
337	OP0114â€¦Improving early recognition of arthritis: Evaluation of the first year results on two early arthritis recognition clinics. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 91.3-92.	0.5	0
338	Profiling the Secretion of Soluble Mediators by End Stage Osteoarthritis Synovial Tissue Explants Reveals a Reduced Responsiveness to an Inflammatory Trigger. <i>PLoS ONE</i> , 2013, 8, e62634.	1.1	4
339	Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 707-709.	0.5	64
340	Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 2118-2126.	1.0	62
341	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 268-274.	0.5	61
342	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 638-641.	0.5	354

#	ARTICLE	IF	CITATIONS
343	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1472-1477.	0.5	86
344	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1366-1369.	0.5	46
345	Genetic predisposition of the severity of joint destruction in rheumatoid arthritis; a population based study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A56.2-A56.	0.5	1
346	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	0.9	26
347	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A52.1-A52.	0.5	0
348	Immunosuppressive DX5+ T cells are potent inhibitors of Th-1 responses via modulation of DCs. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A17.2-A18.	0.5	0
349	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. <i>Nature Genetics</i> , 2012, 44, 1336-1340.	9.4	558
350	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	0.9	115
351	The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 245-248.	0.5	70
352	The influence of ACPA status and characteristics on the course of RA. <i>Nature Reviews Rheumatology</i> , 2012, 8, 144-152.	3.5	173
353	Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 359-365.	0.6	21
354	Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. <i>Scandinavian Journal of Rheumatology</i> , 2012, 41, 15-19.	0.6	8
355	Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. <i>Rheumatology</i> , 2012, 51, 1120-1128.	0.9	38
356	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. <i>Pharmacogenomics</i> , 2012, 13, 1087-1094.	0.6	33
357	Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 1484-1499.	0.6	506
358	Anticytomegalovirus seropositivity in rheumatoid arthritis is not associated with the presence of severe extraarticular complications: Comment on the article by Pierer et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 2803-2804.	6.7	1
359	The additive value of magnetic resonance imaging for bone edema in predicting rheumatoid arthritis development in early undifferentiated arthritis: Comment on the article by Duer-Jensen et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 321-322.	6.7	3
360	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	0.9	15

#	ARTICLE	IF	CITATIONS
361	Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 60-67.	0.5	302
362	Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?. <i>Rheumatology</i> , 2011, 50, 93-100.	0.9	240
363	The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1039-1046.	0.5	155
364	Animal models for arthritis: innovative tools for prevention and treatment. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1357-1362.	0.5	92
365	Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. <i>Arthritis Research and Therapy</i> , 2011, 13, R150.	1.6	79
366	Role of rheumatology clinical nurse specialists in optimizing management of hand osteoarthritis during daily practice in secondary care: an observational study. <i>Journal of Multidisciplinary Healthcare</i> , 2011, 4, 403.	1.1	9
367	Treatment strategies in recent onset rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 241-244.	2.0	13
368	Drug-free remission: is it already possible?. <i>Current Opinion in Rheumatology</i> , 2011, 23, 266-272.	2.0	24
369	Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis. <i>European Journal of Human Genetics</i> , 2011, 19, 908-914.	1.4	13
370	Body mass index and alignment and their interaction as risk factors for progression of knees with radiographic signs of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 1117-1122.	0.6	41
371	Validity of joint space width measurements in hand osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 1349-1355.	0.6	17
372	Genetics of rheumatoid arthritis: what have we learned?. <i>Immunogenetics</i> , 2011, 63, 459-466.	1.2	142
373	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Arthritis and Rheumatism</i> , 2011, 63, 1823-1832.	6.7	55
374	Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2567-2574.	6.7	102
375	Recommendations for publication of genetic association studies in <i>Arthritis & Rheumatism</i> . <i>Arthritis and Rheumatism</i> , 2011, 63, 2839-2847.	6.7	19
376	Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: Relationship to functional capacity and ventricular arrhythmias. <i>Arthritis and Rheumatism</i> , 2011, 63, 3969-3978.	6.7	80
377	State of the art lecture: IP53. Inflammatory Arthritis: Prospects for Next Decade. <i>Rheumatology</i> , 2011, 50, iii11-iii11.	0.9	0
378	Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A21-A21.	0.5	0

#	ARTICLE	IF	CITATIONS
379	<i>PADI4</i> polymorphism predisposes male smokers to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 512-515.	0.5	55
380	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1697-1698.	0.5	6
381	The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. <i>Lupus</i> , 2011, 20, 485-492.	0.8	13
382	Fc-glycosylation of IgG1 is modulated by B cell Stimuli. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A61-A61.	0.5	0
383	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A5-A5.	0.5	0
384	Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1282-1284.	0.5	120
385	Osteophytes and joint space narrowing are independently associated with pain in finger joints in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1835-1837.	0.5	63
386	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 188-193.	0.5	118
387	Which elements of the criteria for RA are stable over time?. <i>Rheumatology</i> , 2011, 50, 248-249.	0.9	1
388	Genetic interaction in the susceptibility of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A84-A84.	0.5	1
389	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17372-17377.	3.3	464
390	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A1-A1.	0.5	3
391	Health care usage in Dutch systemic lupus erythematosus patients. <i>Lupus</i> , 2011, 20, 1147-1154.	0.8	4
392	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1461-1464.	0.5	45
393	Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci. <i>PLoS Genetics</i> , 2011, 7, e1002004.	1.5	307
394	Determinants of absence of osteoarthritis in old age. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 68-73.	0.6	40
395	Association between Several Clinical and Radiological Determinants with Long-Term Clinical Progression and Good Prognosis of Lower Limb Osteoarthritis. <i>PLoS ONE</i> , 2011, 6, e25426.	1.1	22
396	A quantitative approach to early rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2011, 69, 116-21.	0.7	4

#	ARTICLE	IF	CITATIONS
397	Low innate production of interleukin-1 β and interleukin-6 is associated with the absence of osteoarthritis in old age. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 942-947.	0.6	62
398	Doyle Index is a valuable additional pain measure in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 1046-1050.	0.6	21
399	Treatment with TNF- α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 1256-1262.	0.6	65
400	Neutralization of IL-4 reverses the nonresponsiveness of CD4 ⁺ T cells to regulatory T-cell induction in non-responder mouse strains. <i>Molecular Immunology</i> , 2010, 48, 137-146.	1.0	8
401	DX5 ⁺ CD4 ⁺ T cells modulate cytokine production by CD4 ⁺ T cells towards IL-10 via the production of IL-4. <i>European Journal of Immunology</i> , 2010, 40, 2731-2740.	1.6	5
402	Validity of the disease activity score in undifferentiated arthritis. <i>Arthritis Care and Research</i> , 2010, 62, 1392-1398.	1.5	6
403	Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 117-125.	6.7	103
404	Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: A meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. <i>Arthritis and Rheumatism</i> , 2010, 62, 1236-1245.	6.7	135
405	Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. <i>Arthritis and Rheumatism</i> , 2010, 62, 1620-1629.	6.7	183
406	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor α therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
407	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
408	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
409	Long-term impact of delay in assessment of patients with early arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3537-3546.	6.7	357
410	Tract-based spatial statistics on diffusion tensor imaging in systemic lupus erythematosus reveals localized involvement of white matter tracts. <i>Arthritis and Rheumatism</i> , 2010, 62, 3716-3721.	6.7	50
411	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
412	Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. <i>Nature Genetics</i> , 2010, 42, 814-816.	9.4	65
413	Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1554-1561.	0.5	268
414	Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 727-729.	0.5	35

#	ARTICLE	IF	CITATIONS
415	The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1110-1116.	0.5	68
416	Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 585-587.	0.5	106
417	Prevention of autoimmune rheumatic disease: state of the art and future perspectives. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2062-2066.	0.5	83
418	Genetic variants in the prediction of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1694-1696.	0.5	43
419	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203
420	Loss of imprinting of <i>IGF2</i> characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1239-1242.	0.5	11
421	Association between weight or body mass index and hand osteoarthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 761-765.	0.5	332
422	Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1342-1345.	0.5	53
423	Disease Activity Monitoring in Rheumatoid Arthritis in Daily Practice: Experiences with METEOR, a Free Online Tool. <i>Journal of Rheumatology</i> , 2010, 37, 2632-2633.	1.0	11
424	Antibodies to <i>Porphyromonas gingivalis</i> Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives. <i>Journal of Rheumatology</i> , 2010, 37, 1105-1112.	1.0	195
425	Can we achieve true drug-free remission in patients with RA?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 68-70.	3.5	21
426	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 696-699.	0.5	49
427	Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1367-1369.	0.5	107
428	Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 567-570.	0.5	30
429	The joint-gut axis in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 257-268.	0.6	112
430	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
431	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
432	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. <i>Pharmacogenomics</i> , 2010, 11, 163-175.	0.6	64

#	ARTICLE	IF	CITATIONS
433	Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. <i>Journal of Autoimmunity</i> , 2010, 34, 390-399.	3.0	27
434	Rheumatoid arthritis. <i>Lancet</i> , The, 2010, 376, 1094-1108.	6.3	2,712
435	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
436	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 807-812.	0.5	99
437	De Novo Generation and Enhanced Suppression of Human CD4+CD25+ Regulatory T Cells by Retinoic Acid. <i>Journal of Immunology</i> , 2009, 183, 4119-4126.	0.4	98
438	Functional Killer Ig-Like Receptors on Human Memory CD4+ T Cells Specific for Cytomegalovirus. <i>Journal of Immunology</i> , 2009, 182, 4175-4182.	0.4	37
439	Quality indicators in rheumatology: valid for whom?. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1797-1799.	0.5	8
440	Every shared epitope allele for itself?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 477-478.	3.5	2
441	Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1011-1016.	0.5	69
442	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. <i>Drug Discovery Today</i> , 2009, 14, 837-844.	3.2	9
443	The use of data from early arthritis clinics for clinical research. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 117-123.	1.4	10
444	Early Rheumatoid Arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 1-2.	1.4	3
445	DC α -induced CD8 ⁺ T α cell response is inhibited by MHC class II α -dependent DX5 ⁺ CD4 ⁺ Treg. <i>European Journal of Immunology</i> , 2009, 39, 1765-1773.	1.6	9
446	Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 916-923.	6.7	200
447	Confirmation of <i>STAT4</i> , <i>IL2/IL21</i> , and <i>CTLA4</i> polymorphisms in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1255-1260.	6.7	84
448	Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. <i>Arthritis and Rheumatism</i> , 2009, 60, 2262-2271.	6.7	193
449	Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> . 2009, 60, 2232-2241.	6.7	138
450	Association of a single nucleotide polymorphism in <i>CD40</i> with the rate of joint destruction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2242-2247.	6.7	91

#	ARTICLE	IF	CITATIONS
451	Shared symptoms in rheumatic diseases: A blessing or a curse?. <i>Arthritis and Rheumatism</i> , 2009, 60, 2547-2549.	6.7	7
452	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009, 41, 1313-1318.	9.4	306
453	The BeSt story: on strategy trials in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 291-298.	2.0	39
454	A european perspective on the 50th anniversary of Arthritis & Rheumatism. <i>Arthritis and Rheumatism</i> , 2008, 58, S136-S139.	6.7	0
455	Validation of a prediction rule for disease outcome in patients with recent onset undifferentiated arthritis: Moving toward individualized treatment decision-making. <i>Arthritis and Rheumatism</i> , 2008, 58, 2241-2247.	6.7	145
456	Genome-wide single-nucleotide polymorphism studies in rheumatology: Hype or hope?. <i>Arthritis and Rheumatism</i> , 2008, 58, 2591-2597.	6.7	12
457	Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 3000-3008.	6.7	156
458	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. <i>Nature Genetics</i> , 2008, 40, 1216-1223.	9.4	476
459	Translating basic research into clinical rheumatology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 299-310.	1.4	6
460	Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. <i>Arthritis Research and Therapy</i> , 2008, 10, 205.	1.6	128
461	Hyperpigmentation of the skin due to hydroxychloroquine. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 158-158.	0.6	17
462	Gene Therapy and Cement Injection for Restabilization of Loosened Hip Prostheses. <i>Human Gene Therapy</i> , 2008, 19, 83-96.	1.4	25
463	Cutting Edge: TNFR-Shedding by CD4+CD25+ Regulatory T Cells Inhibits the Induction of Inflammatory Mediators. <i>Journal of Immunology</i> , 2008, 180, 2747-2751.	0.4	108
464	Rituximab in relapsing Graves' disease, a phase II study. <i>European Journal of Endocrinology</i> , 2008, 159, 609-615.	1.9	86
465	Lupus and the central nervous system. <i>Lupus</i> , 2008, 17, 376-379.	0.8	18
466	Gene Therapy for the Treatment of Hip Prosthesis Loosening: Adverse Events in a Phase 1 Clinical Study. <i>Human Gene Therapy</i> , 2008, 19, 1029-1038.	1.4	7
467	A Large-Scale Rheumatoid Arthritis Genetic Study Identifies Association at Chromosome 9q33.2. <i>PLoS Genetics</i> , 2008, 4, e1000107.	1.5	75
468	Vascular compromise of a finger due to tenosynovitis. <i>Journal of Rheumatology</i> , 2008, 35, 354.	1.0	1

#	ARTICLE	IF	CITATIONS
469	A Novel Role of Complement Factor C1q in Augmenting the Presentation of Antigen Captured in Immune Complexes to CD8+T Lymphocytes. <i>Journal of Immunology</i> , 2007, 178, 7581-7586.	0.4	29
470	The battle between anti-cyclic citrullinated peptide and rheumatoid factor testsâ€”a winner at last?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 696-697.	3.2	1
471	A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis. <i>PLoS Medicine</i> , 2007, 4, e278.	3.9	232
472	Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. <i>Lupus</i> , 2007, 16, 329-334.	0.8	61
473	Immunomodulatory Dendritic Cells Inhibit Th1 Responses and Arthritis via Different Mechanisms. <i>Journal of Immunology</i> , 2007, 179, 1506-1515.	0.4	86
474	Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19966-19970.	3.3	59
475	Pharmacogenetics in the future treatment of rheumatology. <i>Future Rheumatology</i> , 2007, 2, 337-339.	0.2	0
476	Exploratory analysis of four polymorphisms in humanGGHandFPGSGgenes and their effect in methotrexate-treated rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2007, 8, 141-150.	0.6	57
477	The HLAâ€”DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. <i>Arthritis and Rheumatism</i> , 2007, 56, 425-432.	6.7	124
478	A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions. <i>Arthritis and Rheumatism</i> , 2007, 56, 433-440.	6.7	320
479	Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2007, 56, 1424-1432.	6.7	363
480	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1765-1775.	6.7	225
481	Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1728-1735.	6.7	44
482	Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: Identification of the interleukinâ€”7 signaling pathway in tissues with lymphoid neogenesis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2492-2502.	6.7	156
483	Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. <i>European Journal of Immunology</i> , 2007, 37, 129-138.	1.6	912
484	Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: Short-term results. <i>Joint Bone Spine</i> , 2007, 74, 48-51.	0.8	10
485	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. <i>Drug Discovery Today</i> , 2007, 12, 125-131.	3.2	57
486	N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?. <i>Journal of Rheumatology</i> , 2007, 34, 250-2.	1.0	3

#	ARTICLE	IF	CITATIONS
487	Acitretin-related ossification. <i>Journal of Rheumatology</i> , 2007, 34, 837-8.	1.0	12
488	Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. <i>Arthritis Research and Therapy</i> , 2006, 8, R165.	1.6	80
489	Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. <i>Arthritis Research and Therapy</i> , 2006, 8, 216.	1.6	40
490	Rheumatoid arthritis: the goal rather than the health-care provider is key. <i>Lancet, The</i> , 2006, 367, 450-452.	6.3	13
491	Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. <i>Molecular Immunology</i> , 2006, 43, 2045-2050.	1.0	32
492	HLA and RA Revisited: Citrullinated Food for the SE Hypothesis, the DR6 Effect, and NIMA. <i>Human Immunology</i> , 2006, 67, 454-459.	1.2	15
493	Genetics and clinical characteristics to predict rheumatoid arthritis: where are we now and what are the future prospects?. <i>Future Rheumatology</i> , 2006, 1, 79-89.	0.2	3
494	Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo. <i>Immunology</i> , 2006, 119, 499-506.	2.0	51
495	Genetic markers of treatment response in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2006, 8, 369-377.	2.1	13
496	Arthrography in loosened hip prostheses. Assessment of possibilities for intra-articular therapy. <i>Joint Bone Spine</i> , 2006, 73, 684-690.	0.8	4
497	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. <i>Arthritis and Rheumatism</i> , 2006, 54, 1087-1095.	6.7	188
498	The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1117-1121.	6.7	294
499	Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 2028-2030.	6.7	29
500	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2830-2839.	6.7	123
501	Detection of change in CNS involvement in neuropsychiatric SLE: A magnetization transfer study. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 812-816.	1.9	34
502	Is the tuberculin skin test an accurate method of detecting tuberculosis in patients with rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 188-189.	3.2	1
503	Selective Involvement of the Amygdala in Systemic Lupus Erythematosus. <i>PLoS Medicine</i> , 2006, 3, e499.	3.9	53
504	Immature Dendritic Cells Suppress Collagen-Induced Arthritis by In Vivo Expansion of CD49b+ Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 3806-3813.	0.4	94

#	ARTICLE	IF	CITATIONS
505	Tumor Necrosis Factor- α Genetic Predisposing Factors Can Influence Clinical Severity in Nephropathia Epidemica. <i>Viral Immunology</i> , 2006, 19, 558-564.	0.6	33
506	Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1747-53.	1.0	21
507	Seasonal variation of primary neuropsychiatric systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 1913-4; author reply 1914.	1.0	6
508	Understanding the genetic contribution to rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 299-304.	2.0	92
509	Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. <i>Blood</i> , 2005, 105, 2991-2994.	0.6	12
510	Association of the risk of osteoarthritis with high innate production of interleukin-1 β and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. <i>Arthritis and Rheumatism</i> , 2005, 52, 1443-1450.	6.7	51
511	Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 1999-2002.	6.7	126
512	An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. <i>Arthritis and Rheumatism</i> , 2005, 52, 2637-2644.	6.7	102
513	Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. <i>Arthritis and Rheumatism</i> , 2005, 52, 3433-3438.	6.7	496
514	CTLA4 is differentially associated with autoimmune diseases in the Dutch population. <i>Human Genetics</i> , 2005, 118, 58-66.	1.8	63
515	Tweaking Microtubules to Treat Scleroderma. <i>PLoS Medicine</i> , 2005, 2, e415.	3.9	0
516	Gene Transfer of Tissue Inhibitor of Metalloproteinases-3 Reverses the Inhibitory Effects of TNF- α on Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts. <i>Journal of Immunology</i> , 2005, 174, 6524-6531.	0.4	50
517	Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 2-3.	3.2	16
518	The Devil in the Details: The Emerging Role of Anticitrulline Autoimmunity in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2005, 175, 5575-5580.	0.4	92
519	Redefining the HLA and RA association: To be or not to be anti-CCP positive. <i>Journal of Autoimmunity</i> , 2005, 25, 21-25.	3.0	75
520	IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. <i>Cytokine</i> , 2005, 29, 215-228.	1.4	40
521	Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, R949-58.	1.6	400
522	The effect of corticosteroid medication on quantitative MR parameters of the brain. <i>American Journal of Neuroradiology</i> , 2005, 26, 2475-80.	1.2	11

#	ARTICLE	IF	CITATIONS
523	The role of interleukin 10 promoter polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1571-5.	1.0	18
524	Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. <i>Human Molecular Genetics</i> , 2004, 13, 1755-1762.	1.4	249
525	Inflammation underlying cardiovascular mortality is a late consequence of evolutionary programming. <i>FASEB Journal</i> , 2004, 18, 1022-1024.	0.2	231
526	Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17180-17185.	3.3	69
527	Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. <i>Genes and Immunity</i> , 2004, 5, 592-595.	2.2	69
528	Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. <i>Experimental Gerontology</i> , 2004, 39, 1407-1414.	1.2	105
529	Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2113-2121.	6.7	319
530	Associations, populations, and the truth: Recommendations for genetic association studies in Arthritis & Rheumatism. <i>Arthritis and Rheumatism</i> , 2004, 50, 2066-2071.	6.7	78
531	Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. <i>Quality of Life Research</i> , 2003, 12, 635-644.	1.5	68
532	Interleukin-10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. <i>Immunogenetics</i> , 2003, 54, 896-899.	1.2	50
533	Evidence for non-random distribution of FcÎ³ receptor genotype combinations. <i>Immunogenetics</i> , 2003, 55, 240-246.	1.2	56
534	Genetics in rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2003, 17, 703-716.	1.4	14
535	High innate production of interleukin-10 and tumor necrosis factor-Î± contributes to susceptibility for non-paraneoplastic Lambert-Eaton myasthenic syndrome. <i>Journal of Neuroimmunology</i> , 2003, 140, 194-197.	1.1	17
536	Analysis of allelic expression patterns of IL-2, IL-3, IL-4, and IL-13 in human CD4+ T cell clones. <i>European Journal of Immunology</i> , 2003, 33, 2142-2148.	1.6	8
537	Fibroblast-like synoviocytes from rheumatoid arthritis patients express less FLICE-inhibitory protein than fibroblast-like synoviocytes from trauma patients: Comment on the article by Schedel et al. <i>Arthritis and Rheumatism</i> , 2003, 48, 858-859.	6.7	3
538	Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3 CR1 and rheumatoid arthritis. <i>Tissue Antigens</i> , 2003, 62, 170-174.	1.0	14
539	Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 40967-40972.	1.6	333
540	Allele-Specific Expression of the IL-1Î± Gene in Human CD4+ T Cell Clones. <i>Journal of Immunology</i> , 2003, 171, 2349-2353.	0.4	15

#	ARTICLE	IF	CITATIONS
541	Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus. <i>American Journal of Neuroradiology</i> , 2003, 24, 850-4.	1.2	44
542	Soluble Fc γ RIIIa as a marker for rheumatoid arthritis: the use of genetics in selected populations to study pathogenetic pathways. <i>Journal of Rheumatology</i> , 2003, 30, 1904-6.	1.0	3
543	Systemic Lupus Erythematosus: Diagnostic Application of Magnetization Transfer Ratio Histograms in Patients with Neuropsychiatric Symptoms—Initial Results. <i>Radiology</i> , 2002, 222, 722-728.	3.6	35
544	Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. <i>Human Immunology</i> , 2002, 63, 281-285.	1.2	48
545	Production of IL-1 β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 126, 172-179.	1.1	111
546	Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1155-1159.	6.7	63
547	Genetics in rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2002, 4, 195-200.	2.1	4
548	Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2001, 166, 3915-3922.	0.4	353
549	FUNCTIONAL ANALYSIS OF LINKER-SCAN MUTANTS SPANNING THE γ 376, γ 308, γ 244, AND γ 238 POLYMORPHIC SITES OF THE TNF- α PROMOTER. <i>Cytokine</i> , 2001, 14, 316-323.	1.4	116
550	Imaging modalities in central nervous system systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2001, 13, 383-388.	2.0	48
551	What will treatment of autoimmune diseases entail in 2010?. <i>Seminars in Immunopathology</i> , 2001, 23, 187-192.	4.0	0
552	The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. <i>Arthritis and Rheumatism</i> , 2001, 44, 48-52.	6.7	34
553	Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. <i>Arthritis and Rheumatism</i> , 2001, 44, 570-577.	6.7	41
554	Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2001, 44, 1515-1524.	6.7	368
555	The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 2525-2530.	6.7	184
556	Optimizing human fertility and survival. <i>Nature Medicine</i> , 2001, 7, 873-873.	15.2	83
557	Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. <i>Genes and Immunity</i> , 2001, 2, 135-144.	2.2	85
558	Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF α 308A in systemic lupus erythematosus. <i>Genes and Immunity</i> , 2001, 2, 373-380.	2.2	51

#	ARTICLE	IF	CITATIONS
559	OP0145â€¦Gene-environment and disease interactions: is it smart to use cohort studies?. , 2001, , .		0
560	Diabetes insipidus in metastatic cancer: Two case reports with review of the literature. <i>Annals of Oncology</i> , 2000, 11, 891-895.	0.6	22
561	Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. <i>Annals of Neurology</i> , 2000, 48, 641-646.	2.8	47
562	Feasibility of Adenovirus-Mediated Nonsurgical Synovectomy in Collagen-Induced Arthritis-Affected Rhesus Monkeys. <i>Human Gene Therapy</i> , 1999, 10, 1139-1149.	1.4	63
563	Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. <i>Genes and Immunity</i> , 1999, 1, 91-96.	2.2	57
564	Polymorphism within the tumor necrosis factor $\hat{\pm}$ (TNF) promoter region in patients with ankylosing spondylitis. <i>Human Immunology</i> , 1999, 60, 140-144.	1.2	40
565	Determination of tumour necrosis factor- $\hat{\pm}$ and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. <i>Journal of Immunological Methods</i> , 1998, 218, 63-71.	0.6	126
566	An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. <i>Immunogenetics</i> , 1998, 48, 394-401.	1.2	58
567	Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. <i>Lancet, The</i> , 1998, 352, 1282-1283.	6.3	104
568	Interleukin 10 secretion in relation to human IL-10 locus haplotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9465-9470.	3.3	458
569	Genetic influence on cytokine production in meningococcal disease. <i>Lancet, The</i> , 1997, 349, 1912-1913.	6.3	159
570	Genetic influence on cytokine production and fatal meningococcal disease. <i>Lancet, The</i> , 1997, 349, 170-173.	6.3	757
571	TNF- $\hat{\pm}$ promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. <i>Journal of Neuroimmunology</i> , 1997, 72, 149-153.	1.1	214
572	Cytokine-Suppressive Anti-Inflammatory Drugs. <i>BioDrugs</i> , 1996, 6, 395-404.	0.7	1
573	Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. <i>Kidney International</i> , 1996, 49, 403-412.	2.6	41
574	Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. <i>Human Genetics</i> , 1996, 97, 813-818.	1.8	1
575	Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. <i>Human Genetics</i> , 1995, 96, 493.	1.8	35
576	Changes in Plasma FcRIII Demonstrate Increasing Receptor Production during Late Pregnancy and after Preterm Birth. <i>Pediatric Research</i> , 1992, 32, 505-508.	1.1	19

#	ARTICLE	IF	CITATIONS
577	5 Fc-gamma receptors: mediators, targets and markers of disease. Best Practice and Research: Clinical Haematology, 1991, 4, 889-902.	1.1	4
578	Reactivity of cloned, expressed human Fc γ RIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of Fc γ RIII. International Immunology, 1990, 2, 303-310.	1.8	29
579	The Pi-linked receptor FcRIII is released on stimulation of neutrophils. Nature, 1988, 333, 667-669.	13.7	395
580	On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	1
581	Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort. Scandinavian Journal of Rheumatology, 0, , 1-4.	0.6	0